LBLTF (Lattice Biologics) Cash per Share: $0.00 (As of Jun. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lattice Biologics Cash per Share?

Lattice Biologics LBLTF -99.00% Cash per Share is $0.00 as of Jun. 2021.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Lattice Biologics's Cash per Share for the quarter that ended in Jun. 2021 was $0.00.


Lattice Biologics  (OTCPK:LBLTF) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Lattice Biologics Cash per Share Related Terms


Lattice Biologics Cash per Share Historical Data

* Premium members only.

The historical data trend for Lattice Biologics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lattice Biologics Cash per Share Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lattice Biologics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Lattice Biologics's Cash per Share for the fiscal year that ended in Sep. 2020 is calculated as:

Lattice Biologics's Cash per Share for the quarter that ended in Jun. 2021 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $0.00 mean?
Lattice Biologics (LBLTF) has a Cash per Share of $0.00 as of Jun. 2021. Cash per share is the per-share value of a company's available cash. View historical data for Lattice Biologics and its competitors.
Is Lattice Biologics' Cash per Share too high?
Lattice Biologics' current Cash per Share is $0.00.
How does Lattice Biologics' Cash per Share compare to ABT and MDT?
Lattice Biologics' Cash per Share of $0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Medical Devices & Instruments company?
A good Cash per Share depends on the Medical Devices & Instruments industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Lattice Biologics and its competitors. Lattice Biologics's current Cash per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current Cash per Share of $0.00. The current Cash per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current Cash per Share is $0.00 as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.